In vitro chloroquine resistance for Plasmodium vivax isolates from the Western Brazilian Amazon by Yonne F Chehuan et al.
Chehuan et al. Malaria Journal 2013, 12:226
http://www.malariajournal.com/content/12/1/226RESEARCH Open AccessIn vitro chloroquine resistance for Plasmodium
vivax isolates from the Western Brazilian Amazon
Yonne F Chehuan1, Monica RF Costa1, Jacqueline S Costa1, Maria GC Alecrim1,2, Fátima Nogueira3,
Henrique Silveira3, Larissa W Brasil1,2, Gisely C Melo1,2, Wuelton M Monteiro1,2* and Marcus VG Lacerda1,2,4Abstract
Background: Chloroquine (CQ) and primaquine (PQ) are still the drugs of choice to treat Plasmodium vivax malaria
in many endemic areas, Brazil included. There is in vivo evidence for the P. vivax resistance to CQ in the Brazilian
Amazon, where the increase in the proportion of P. vivax malaria parallels the increase of unusual clinical
complications related to this species. In this study, in vitro CQ and mefloquine (MQ)-susceptibility of P. vivax isolates
from the Western Brazilian Amazon was tested using the double-site enzyme-linked lactate dehydrogenase
immunodetection (DELI) assay.
Methods: A total of 112 P. vivax isolates were tested in vitro for CQ-susceptibility and out of these 47 were also
tested for MQ-susceptibility. The DELI assay was used to detect P. vivax growth at 48-hour short-term culture in
isolates with ring stages ranging from 50 to 70%. Each isolate was tested in triplicate and geometric means of
IC50’s was obtained. Nineteen isolates were genetically characterized for pvdhfr, pvmrp1, pvmdr1 and pvdhps
candidate genes likely related to CQ resistance (10 with IC50<40 nM and 9 with IC50 >100 nM).
Results: Twelve out of 112 isolates were considered resistant to CQ, resulting in 10.7% (IC95% 5.0-16.4), while 3 out
of 47 (6.4%; IC95% 0.0-12.8) were resistant to MQ. A discrete correlation was observed between IC50’s of CQ and
MQ (Spearman=0.294; p=0.045). For pvdhps gene, a non-synonymous mutation was found at codon 382 (S→C) in
5/8 CQ-sensitive samples and 1/9 CQ-resistant samples (p=0.027). The other molecular markers were not associated
to CQ-susceptibility.
Conclusions: In vitro CQ-resistance estimated in this study, estimated by the DELI test, was very similar to that
observed in clinical trials, suggesting that in vitro procedures developed by capable local laboratories are useful in
the surveillance of CQ-resistance in the Amazon; concurrent Amazon P. vivax strains with both CQ and MQ
resistance may be common; and a non-synonymous mutation at pvdhps codon 382 (S→C) was associated to
in vitro susceptibility to CQ, needing further studies to be confirmed.
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Plasmodium vivax remains more widely distributed than
Plasmodium falciparum and is a potential cause of mor-
bidity and mortality amongst the 2.85 billion people liv-
ing at risk of infection, the majority of whom are in the
tropical belt of Central and Southeastern Asia and Latin
America [1]. In Brazil, P. vivax is responsible for more* Correspondence: wueltonmm@ibest.com.br
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reproduction in any medium, provided the orthan 80% of the cases in the last years [2]. In this coun-
try, the increase in the proportion of P. vivax malaria
parallels the increase in the frequency of unusual clinical
complications in P. vivax-infected patients [3]. Chloro-
quine (CQ) and primaquine (PQ) are still the drugs of
choice to treat vivax malaria in many endemic areas,
Brazil included. The simultaneous occurrence of severe
vivax disease and CQ-resistance in some countries has
raised the question of a possible association between
severity and resistance [4]. CQ-resistance actually has
been reported in Brazil almost at the same time as
clinical severity [5].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resistance in the Brazilian Amazon. In this region, the
resistance to CQ was firstly reported in Manaus in 1999
[5]. More recent data from studies conducted in the
RAVREDA multicenter study (Amazonian Network for
Surveillance for Resistance to Antimalarial Drugs) with a
proper follow-up of patients exclusively using CQ and in
whom drug plasma concentration was evaluated, seem
to confirm such an observation [5]. However, since CQ
plus PQ, the drug association used for the radical cure
of P. vivax infection, has a synergistic action [6], further
studies are needed to evaluate the contribution of CQ by
itself for the effectiveness of the drug association, before
any definitive conclusion can be proposed.
In vitro surveillance of anti-malarials resistance is largely
used in P. falciparum with public health purposes, how-
ever P. vivax can grow only to a certain extent under
in vitro conditions, with a very low reinvasion rate, what
poses technical limitations to the routine use of this ap-
proach. The first in vitro P. vivax short-term culture was
performed in 1974 [7], but more recent publications have
presented reproducible results based on the WHO
microtest using quantification of schizont maturation [8].
The method is cheap, however it is time-consuming since
slides from the drug-free well have to be made every 6
hours trying to achieve the moment when there is schiz-
onts maturation of 40%. Even demanding monoclonal
antibodies, what makes it more expensive, the double-site
Plasmodium lactate dehydrogenase (LDH) antigen capture
enzyme-linked immunosorbent assay (DELI) [9] quantifies
the total pLDH produced by maturing stages, and can be
performed in 48 hours after the beginning of the culture,
avoiding sequential slides reading. The aim of this study
was to estimate the in vitro CQ-susceptibility of P. vivax
isolates from the Western Brazilian Amazon using the
DELI assay.
Methods
Site of study and patients
The study was performed from December 2007 to July
2008 in the Fundação de Medicina Tropical Dr. Heitor
Vieira Dourado (FMT-HVD), which reports 30% of all
the malaria cases in Manaus (03°06′S, 60°01′W). Pa-
tients living in the urban or peri-urban areas of this city
with uncomplicated P. vivax malaria confirmed by a
thick blood smear (TBS) were randomly selected in the
outpatient clinics, from which epidemiological and clinical
history was fully obtained. Parasite densities with differen-
tial counting of rings, trophozoites and schizonts were es-
timated by experienced microscopists, by counting the
number of parasites in 200 leukocytes in high magnifica-
tion fields, and the number of leukocytes/mm3. The study
included patients of both sexes, aged 12–60 years, pre-
senting blood parasite density from 250 to 100,000parasites/mm3 and axillary temperature ≥ 37.5°C or his-
tory of fever in the last 48 hours. The major exclusion cri-
terion was the use of anti-malarials in the previous
60 days. Due to the selective action of CQ upon
young P. vivax trophozoites (rings) [10], only samples
with ring stages ranging from 50-70% at the initial
counting were analysed in this study.
In vitro determination of susceptibility to drugs
Blood samples were collected in on Vacutainer (Becton
Dickinson®, Oxnard, CA) EDTA tubes prior to patient
treatment. CQ sulfate and MQ hydrochloride were
obtained from Sigma-Aldrich®. Isolates from the same
outpatient clinics were randomly selected (47 were
tested for CQ and MQ susceptibility and additional 65
samples were tested only for CQ). The blood samples
were washed twice with a solution of RPMI-1640
Medium (Gibco®) and then one time with culture
complete medium. The blood samples were then
resuspended in the complete culture medium to obtain
a 1.5% haematocrit. Finally, 200 μL of this suspension
were distributed to each well in the anti-malarial pre-
dosed plates. The plates were systematically incubated
for 48h at 37°C (5% CO2, 5% O2 and 90% N2) and were
immediately frozen at −20°C until the DELI test was
performed with many samples at the same time. Only
cultures with viable schizonts at 48 hours were consid-
ered valid. For the DELI test, plates were frozen and
thawed three times to haemolyse the culture and release
pLDH [9]. Each isolate was tested in triplicate and geo-
metric means of IC50’s was obtained. IC50 threshold cri-
terion for resistance to CQ or MQ was similar to that
described elsewhere [9]. Dd2 and 3D7 P. falciparum
clones were used as controls.
Molecular characterization
Nineteen isolates were genetically characterized for a
few candidate genes linked to CQ resistance (10 with
IC50<40 nM and 9 with IC50 >100 nM). Whole DNA
extraction was carried out using a QIAamp® DNA Mini
Kit (QIAGEN®, Germany) according to the manufac-
turer’s protocol. PCR primers and different reaction con-
ditions used to amplify P. vivax dihydrofolate reductase
(pvdhfr), multidrug resistance-associated protein 1
(pvmrp1), multidrug resistance 1 (pvmdr-1) locus, and
dihydropteroate synthase (pvdhps) gene sequences were
made as previously described [11-16] (Additional file 1).
Briefly, after initial denaturing at 94°C for 2 minutes, the
samples were submitted to 35 cycles (94°C for 1 minute
more, 58°C for 30 seconds, and 72°C for 1 minute), with a
final extension at 72°C for 10 minutes. For each fragment,
PCR products were visualized by 1% agarose gel electrophor-
esis stained with ethidium bromide to confirm single
band. DNA concentration was measured by NanoDrop®
Figure 1 Distribution of IC50’s (nM) among 112 Plasmodium
vivax isolates from Manaus cultured in the presence of various
concentrations of chloroquine (CQ) or mefloquine (MQ). The
horizontal bars represent the likely thresholds between sensitivity
and resistance.
Figure 2 Spearman correlation between IC50’s of chloroquine
and mefloquine for Plasmodium vivax isolates.
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ried out using an ABI 3130xl genetic analyzer (Applied
Biosystems®, USA) as specified by manufacturer’s protocol.
Data analysis
IC50 was calculated in the software Analysis of Malaria
In Vitro Drug Sensitivity Data (HN-NonLin V 1.05
Beta®). Correlation between CQ and MQ IC50 was cal-
culated through Pearson test. Fisher’s test was employed
to evaluate the association between point mutations and
CQ-resistance. Analysis was performed using SPSS soft-
ware for Windows (version 16; SPSS, Inc., Chicago, IL®).
P<0.05 was considered significant.
Ethical procedures
Collection of human samples and all study procedures
were approved by the Ethical Review Committee of
Fundação de Medicina Tropical Dr. Heitor Vieira
Dourado (protocol number 1850/2007). Written in-
formed consent was obtained from all the participant
patients. All malaria cases were treated according to the
Brazilian Ministry of Health’s National guidelines, with
CQ and PQ.
Results
Twelve out of 112 isolates were considered resistant to
CQ, resulting in 10.7% (CI95% 5.0-16.4) of CQ-
resistance, while three out of 47 (6.4%) (CI95% 0.0-12.8)
were resistant to MQ (Figure 1). A discrete correlation
was observed between IC50’s of CQ and MQ
(Spearman=0.294; p=0.045) (Figure 2).
As seen in the Table 1, for pvdhps gene, a non-
synonymous mutation at codon 382 (S→C) was found
in 5/8 samples in vitro sensitive and 1/9 samples in vitro
resistant to CQ (p=0.027). The other molecular markers
were not associated to CQ susceptibility.
Discussion
Plasmodium vivax in vitro CQ-resistance levels in Latin
America are unknown. In 2007, the proper 28 days
follow-up of 109 patients with P. vivax prescribed only
with CQ lead to the unexpected confirmation of 10.1%
of resistance after plasmatic drug dosage [17], a rate very
similar to that obtained from this study, suggesting that
in vitro procedures developed by capable local laborator-
ies are useful to the surveillance of CQ-resistance in the
Amazon.
An interesting finding of this study was the concurrent
resistance to both CQ and MQ within P. vivax strains
from Amazon. In this region, a CQ-resistance rate of
around 10% requires the evaluation of alternative drugs
such MQ. Although MQ was thought to be a useful al-
ternative treatment for P. vivax malaria in [18] and in-
direct evidence suggested that this drug may beefficacious against CQ-resistant P. vivax in Indonesian
New Guinea [19], there is no previous information from
Latin America supporting these data. In 1999, Alecrim
et al. [5] reported a case of a patient with P. vivax mal-
aria who showed resistance to chloroquine and
Table 1 Frequency of polymorphisms in the pvdhfr,
pvmrp1, pvmdr1 and pvdhps genes for sensitive and







58 7/10 (70%) 8/9 (88.9%) 0.313
117 8/10 (80%) 8/9 (88.9%) 0.596
173 1/10 (10%) 0/9 (0%) 0.330
pvmrp1
1282 9/9 (100%) 7/7 (100%) NS
1393 9/9 (100%) 7/7 (100%) NS
1419 4/9 (44.4%) 2/7 (28.6%) 0.515
1478 10/10 (100%) 9/9 (100%) NS
1586 2/10 (20%) 2/9 (22.2%) 0.906
pvmdr1
908 1/10 (10%) 1/9 (11.1%) 0.937
958 10/10 (100%) 8/9 (8.9%) 0.279
Pvdhps
205 10/10 (100%) 9/9 (100%) NS
382 5/8 (62.5%) 1/9 (11.1%) 0.027
383 0/8 (0%) 1/9 (11.1%) 0.331
NS not significant.
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MQ-resistance overlap have also had commonly
reported from Thailand [20]. Nomura [21] pointed to
different mechanisms of resistance between the two spe-
cies, however some data including results presented here
show that caution is required.
Among the isolates with IC50 defined, 19 have been
genetically characterized (10 with IC50<40 nM and nine
with IC50 >100 nM). For pvdhps gene, a non-
synonymous mutation was found at codon 382 (S→C)
in 5/8 samples in vitro sensitive and 1/9 samples in vitro
resistant (p=0.027). It is known that the spread of
sulphadoxine-pyrimethamine in P. falciparum exerted
selective pressure for pvdhps mutations in P. vivax. Mo-
lecular studies on a population basis for P. falciparum
have demonstrated that patients who were infected with
parasites that carried this mutation may not respond to
treatment [14], but when the parasite carries highly mu-
tant versions of pvdhps and pvdhfr genes, clinical effect-
iveness is compromised [22]. Another study showed that
resistance-conferring mutations were not found in
pvdhps [23]. The other genetic markers were not associ-
ated with drug response. Suwanarusk et al. [24] studying
the same gene, found that CQ IC50 was significantly
higher in P. vivax isolates carrying the Y976F mutation
than in isolates with the wild-type allele. Ranjitkar et al.
[25] found that the low resistance to CQ was due to thelow prevalence of mutation Y976F in pvmdr1 (5%).
However, most studies did not find any association be-
tween mutation in the pvmdr-1 gene and CQ-resistance
corroborating these results [16,21,26,27].
Major limitations of this study were: (1) the small
number of samples; (2) the lack a standard cut-off IC50
for the characterization of resistance in Latin American
samples; (3) DELI test is a less time-consuming test due
to the detection of pLDH in 48-hour culture plates,
however it was never validated as compared to the mi-
croscopy test; (4) in vitro resistance was not individually
compared to in vivo resistance. On the other hand,
standard techniques are not easily reproducible among
the different scenarios in endemic areas, due to
personnel, reagents laboratory conditions. Data from the
same laboratories over time is more reliable information
and may be used as a baseline for future further studies
using the same technique. This paper presents prelimin-
ary data on the in vitro P. vivax resistance in the West-
ern Amazon. More information is needed regarding the
usefulness of this approach in detecting in vivo resist-
ance and the association of more severe cases.
Conclusion
In summary, this study has shown that: 1) in vitro CQ-
resistance estimated in this study was very similar to that
obtained from clinical trials in the same area [17],
suggesting that in vitro procedures developed by capable
local laboratories are useful in the surveillance of the
CQ-resistance in the Amazon; 2) P. vivax strains simul-
taneous resistance to both CQ and MQ within in the
Amazon needs to be clarified; and 3) a non-synonymous
mutation at pvdhps gene codon 382 (S→C) was associ-
ated to in vitro susceptibility to CQ.
The high levels of anti-malarial drug resistance in this
region call for reinforced surveillance of drug efficacy.
Plasmodium vivax CQ-resistance may be rising in the
Brazilian Amazon and probably this fact is contributing
to spread vivax malaria and clinical severity of this dis-
ease. However, the public health urgency to detect and
measure the progression of CQ-resistant vivax malaria
has been neglected. To maintain an efficient malaria
control programme, drug resistance surveillance assays
must be conducted on a regular basis to assess anti-
malarial efficacy and to ensure that the information is
available to policy makers.
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